Genentech may have long been a subsidiary of Roche in accounting terms, but the US biotech group has until now guarded a fierce ­cultural independence from its Swiss majority shareholder.

More than nine months after an increasingly bitter takeover battle began, the ownership will become unambiguous following Genentech’s acceptance of Roche’s revised $95-a-share bid to acquire the 44 per cent it does not currently own.